Aims: While obesity is linked to increased cancer risk, evidence on the impact of intentional weight loss on obesity‐associated cancers (OACs) is limited. A systematic literature review (SLR) was conducted to assess the association between intentional weight loss and cancer incidence, including overall cancers and 13 OACs, from recent observational studies and clinical trials. Methods: Studies published between January 2019 and May 2023 were searched within MEDLINE, EMBASE, and CENTRAL. Studies assessing the relationship between intentional weight loss, defined as weight reduction via metabolic‐bariatric surgery (MBS) or lifestyle interventions, and cancer incidence were included. A dual independent review process was used to screen 1954 abstracts and 84 full‐text articles, and to extract data from 18 full studies. All discrepancies were resolved by another reviewer. Results: Of the 18 studies included, 17 studies were observational, focusing on MBS as the method for achieving weight reduction. One randomised controlled trial examined the effect of intensive lifestyle intervention on weight reduction and found no significant association between intentional weight loss and cancer risk. Intentional weight loss was associated with decreased cancer incidence in 71.4% ( n = 5/7) of studies for all cancers and 66.7% ( n = 4/6) of studies for OACs, with reported risk reductions of 11% to 33% and 11% to 41%, respectively. For specific OACs, a greater number of studies indicated that weight reduction was associated with reduced occurrence of endometrial (4/4, 100%, 31%–53% risk reduction), female breast (5/9, 55.6%, 19%–50% risk reduction) and colorectal (4/7, 57.1%, 20%–60% risk reduction) cancers. Conclusions: This SLR highlights the potential cancer risk‐reduction benefit of weight reduction for people with obesity.
Objectives: This study described real-world patient characteristics and outcomes among selpercatinib-treated patients in the United States, using the Flatiron Health electronic health record-derived deidentified database (FHD) for advanced/metastatic non-small cell lung cancer (a/mNSCLC) and Optum’s de-identified Clinformatics® Data Mart Database (CDM). Methods: Patients initiating selpercatinib treatment between 08MAY2020 and 30JUN2023 were included. We evaluated real-world time to selpercatinib treatment discontinuation or death (rwTTDd) and time to next treatment or death (rwTTNTd) using Kaplan–Meier analyses. Medication possession ratio (MPR) was estimated as a measure of medication adherence in CDM patients. Results: In a/mNSCLC patients from the FHD (N = 68), the median rwTTDd and rwTTNTd were 22.4 [95%CI: 13.3–NR] and 21.0 [95%CI: 11.6–NR] months, respectively. In CDM, these durations were 12.1 [95%CI: 9.6–NR] and 16.2 [95%CI: 9.6–NR] months for lung cancer (n = 43), while these were not reached for thyroid cancer (n = 24) patients. The median MPR was 0.98 [IQR: 0.84–1.00] among all patients in the CDM (N = 75), with 77.3% of patients adhering (MPR ≥ 0.80) to selpercatinib. Conclusions: Real-world outcomes in this older and frailer patient cohort align with phase 3 trial results, further supporting selpercatinib as the standard of care for patients with RET-altered cancers. Early testing for the detection of RET alterations remains essential.
5 April 2024 in Journal of the National Comprehensive Cancer Network
"HSR24-128: Real-World Treatment Patterns and Effectiveness of Selpercatinib in Patients With Locally Advanced/Metastatic Non–Small Cell Lung Cancer in the US" published on 05 Apr 2024 by National Comprehensive Cancer Network.
5 April 2024 in Journal of the National Comprehensive Cancer Network
"EPR24-109: Intentional Weight Loss and Associated Cancer Incidence Among Patients With Overweight or Obesity: A Systematic Literature Review" published on 05 Apr 2024 by National Comprehensive Cancer Network.